BioLineRx Licenses Anti-Cancer Compound From Israeli Universities
 
BioLineRx last week said that it has gained an exclusive worldwide license to the small molecule BL-4060 from Yissum, the technology-transfer arm of the Hebrew University of Jerusalem, and Hadasit, the tech-transfer company of Hadassah medical organization.
 
BL-4060 is an analog of the fatty molecule ceramide for the treatment of cancer. Ceramide is a strong pro-apoptotic agent that induces apoptosis in a variety of cancer cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.